Lisa Barr MD
- PRP Therapy
- Ozone Therapy
- IV Therapy
- Laser Therapy (LLLT)
- Arthritis Treatment
Virginia Beach, VA
Stem Cell Therapy clinics in Virginia Beach
Virginia Beach supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Sentara Virginia Beach General and Chesapeake Regional, and stem cell practice in the area spans Town Center, Hilltop, and the Oceanfront corridor. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Virginia regulates physician practice through the Virginia Board of Medicine. There is no Virginia-specific stem cell statute, so federal 21 CFR Part 1271 rules apply. The 7 Virginia Beach clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Virginia Board of Medicine licensure checks.
MD on staff
QC Kinetix (Virginia Beach)
- PRP Therapy
- Laser Therapy (LLLT)
- Arthritis Treatment
- Stem Cell Therapy
Barr Center for Innovative Pain & Regenerative Therapies
- PRP Therapy
- IV Therapy
- Arthritis Treatment
- Red Light Therapy
- Peptide Therapy
OPMSM - Ocean front Pain management and Sports Medicine
- Arthritis Treatment
- Migraine Treatment
- Stem Cell Therapy
Regulatory context
A note on Virginia's stem cell therapy rules.
Virginia cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Virginia for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. Northern Virginia clinics often draw patients from the District of Columbia.
-
Virginia Medical Practice Act, Code of Virginia Title 54.1, Chapter 29
Establishes physician licensure and discipline through the Virginia Board of Medicine. -
Virginia Pharmacy Practice Act, Code of Virginia Title 54.1, Chapter 33
Regulates compounding pharmacies aligned with federal 503A and 503B standards. -
Virginia Consumer Protection Act, Code of Virginia Title 59.1, Chapter 17
Empowers the Attorney General and private plaintiffs to pursue deceptive marketing claims against providers making unsupported clinical claims.
The FDA has corresponded with Virginia providers offering cellular therapies, and warning letters have been issued to regional clinics. The Virginia Board of Medicine has disciplined physicians for unprofessional conduct including misleading regenerative medicine advertising. The Virginia Attorney General has used the Virginia Consumer Protection Act to pursue providers making unsupported clinical claims. Virginia's proximity to FDA headquarters in Maryland keeps Northern Virginia clinics under close federal observation.